Pharmacogenomic of LH and its receptor: are we ready for clinical practice?
Abstract Luteinizing hormone (LH) is fundamental to support development and reproduction. It acts through a receptor expressed in the gonads, modulating mitogenic, anti-apoptotic, and steroidogenic signals. LH is also marketed as a drug for controlled ovarian stimulation (COS), where it is administe...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Reproductive Biology and Endocrinology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12958-025-01359-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725179873198080 |
|---|---|
| author | Alessandro Conforti Raffaella Di Girolamo Maurizio Guida Carlo Alviggi Livio Casarini |
| author_facet | Alessandro Conforti Raffaella Di Girolamo Maurizio Guida Carlo Alviggi Livio Casarini |
| author_sort | Alessandro Conforti |
| collection | DOAJ |
| description | Abstract Luteinizing hormone (LH) is fundamental to support development and reproduction. It acts through a receptor expressed in the gonads, modulating mitogenic, anti-apoptotic, and steroidogenic signals. LH is also marketed as a drug for controlled ovarian stimulation (COS), where it is administered to women to support the action of follicle-stimulating hormone and can lead to specific responses, depending on the individual genetic background. These concepts underline the relevance of a pharmacogenetic approach to COS, in the attempt to optimize clinical outcomes and avoid adverse events. However, knowledge is currently limited by the paucity of clinical studies. This review aims to provide a comprehensive overview of LH and its receptor activity, starting from the description of their molecular pathways from in vitro studies. Data on LH action from in vivo studies were described, as well as the impact of LH and LH/choriogonadotropin (hCG) receptor genetic variants on folliculogenesis and its association with infertility or polycystic ovarian syndrome. Finally, evidence from clinical studies evaluating genetic polymorphisms in the context of assisted reproductive technology treatments and its implications for a pharmacogenomic approach were discussed. |
| format | Article |
| id | doaj-art-168ad907252d409fa6c46ff5d9b58b8d |
| institution | DOAJ |
| issn | 1477-7827 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Reproductive Biology and Endocrinology |
| spelling | doaj-art-168ad907252d409fa6c46ff5d9b58b8d2025-08-20T03:10:32ZengBMCReproductive Biology and Endocrinology1477-78272025-02-0123S111210.1186/s12958-025-01359-2Pharmacogenomic of LH and its receptor: are we ready for clinical practice?Alessandro Conforti0Raffaella Di Girolamo1Maurizio Guida2Carlo Alviggi3Livio Casarini4Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico IIDepartment of Public Health, University of Naples Federico IIDepartment of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico IIDepartment of Public Health, University of Naples Federico IIUnit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio EmiliaAbstract Luteinizing hormone (LH) is fundamental to support development and reproduction. It acts through a receptor expressed in the gonads, modulating mitogenic, anti-apoptotic, and steroidogenic signals. LH is also marketed as a drug for controlled ovarian stimulation (COS), where it is administered to women to support the action of follicle-stimulating hormone and can lead to specific responses, depending on the individual genetic background. These concepts underline the relevance of a pharmacogenetic approach to COS, in the attempt to optimize clinical outcomes and avoid adverse events. However, knowledge is currently limited by the paucity of clinical studies. This review aims to provide a comprehensive overview of LH and its receptor activity, starting from the description of their molecular pathways from in vitro studies. Data on LH action from in vivo studies were described, as well as the impact of LH and LH/choriogonadotropin (hCG) receptor genetic variants on folliculogenesis and its association with infertility or polycystic ovarian syndrome. Finally, evidence from clinical studies evaluating genetic polymorphisms in the context of assisted reproductive technology treatments and its implications for a pharmacogenomic approach were discussed.https://doi.org/10.1186/s12958-025-01359-2LHLHCGRGenetic variantsPharmacogenomicIVFOvarian stimulation |
| spellingShingle | Alessandro Conforti Raffaella Di Girolamo Maurizio Guida Carlo Alviggi Livio Casarini Pharmacogenomic of LH and its receptor: are we ready for clinical practice? Reproductive Biology and Endocrinology LH LHCGR Genetic variants Pharmacogenomic IVF Ovarian stimulation |
| title | Pharmacogenomic of LH and its receptor: are we ready for clinical practice? |
| title_full | Pharmacogenomic of LH and its receptor: are we ready for clinical practice? |
| title_fullStr | Pharmacogenomic of LH and its receptor: are we ready for clinical practice? |
| title_full_unstemmed | Pharmacogenomic of LH and its receptor: are we ready for clinical practice? |
| title_short | Pharmacogenomic of LH and its receptor: are we ready for clinical practice? |
| title_sort | pharmacogenomic of lh and its receptor are we ready for clinical practice |
| topic | LH LHCGR Genetic variants Pharmacogenomic IVF Ovarian stimulation |
| url | https://doi.org/10.1186/s12958-025-01359-2 |
| work_keys_str_mv | AT alessandroconforti pharmacogenomicoflhanditsreceptorarewereadyforclinicalpractice AT raffaelladigirolamo pharmacogenomicoflhanditsreceptorarewereadyforclinicalpractice AT maurizioguida pharmacogenomicoflhanditsreceptorarewereadyforclinicalpractice AT carloalviggi pharmacogenomicoflhanditsreceptorarewereadyforclinicalpractice AT liviocasarini pharmacogenomicoflhanditsreceptorarewereadyforclinicalpractice |